Trial Profile
A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Colitis; Cytomegalovirus retinitis; End-organ damage; Pancreatitis
- Focus Therapeutic Use
- 12 Oct 2005 New trial record.